Involvement of the IL-23/IL-17 axis and the Th17/Treg balance in the pathogenesis and control of autoimmune arthritis

Cytokine

Volumn 74, Issue 1, 2015, Pages 54-61

  Astry, Brian ^a   Venkatesha, Shivaprasad H ^a   Moudgil, Kamal D ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Arthritis; Interleukin 17; Interleukin 23; Regulatory T cell; T helper 17

Indexed keywords

BRIAKINUMAB; BRODALUMAB; CELASTROL; DIGOXIN; EPIGALLOCATECHIN GALLATE; GUSELKUMAB; HALOFUGINONE; INTERLEUKIN 1; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 6; IXEKIZUMAB; PLACEBO; PROANTHOCYANIDIN; RETINOID RELATED ORPHAN RECEPTOR GAMMA; RETINOID RELATED ORPHAN RECEPTOR GAMMA T; SECUKINUMAB; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; USTEKINUMAB; IL17A PROTEIN, HUMAN;

ANKYLOSING SPONDYLITIS; ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; BONE INJURY; CELL ACTIVITY; DRUG SAFETY; HUMAN; IMMUNOPATHOGENESIS; INHIBITION KINETICS; LYMPHOCYTE DIFFERENTIATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIATIC ARTHRITIS; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; SYNOVITIS; TH17 CELL; ANIMAL; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; EXPERIMENTAL ARTHRITIS; IMMUNOLOGY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; TH1 TH2 BALANCE;

ANIMALS; ARTHRITIS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; HUMANS; INTERLEUKIN-17; INTERLEUKIN-23; T-LYMPHOCYTES, REGULATORY; TH1-TH2 BALANCE; TH17 CELLS;

EID: 84930178055     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2014.11.020     Document Type: Article

References (147)

1. Mosmann T.R., Cherwinski H., Bond M.W., Giedlin M.A., Coffman R.L. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986, 136:2348-2357.
2. Mosmann T.R., Coffman R.L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989, 7:145-173.
3. Mosmann T.R., Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996, 17:138-146.
4. D'Elios M., Del Prete G. Th1/Th2 balance in human disease. Transpl Proc 1998, 30:2373-2377.
5. Cua D.J., Sherlock J., Chen Y., Murphy C.A., Joyce B., Seymour B., et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003, 421:744-748.
6. Murphy C.A., Langrish C.L., Chen Y., Blumenschein W., McClanahan T., Kastelein R.A., et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003, 198:1951-1957.
7. Stritesky G.L., Yeh N., Kaplan M.H. IL-23 promotes maintenance but not commitment to the Th17 lineage. J Immunol 2008, 181:5948-5955.
8. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
9. Gaffen S.L., Jain R., Garg A.V., Cua D.J. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev 2014, 14:585-600.
10. Lubberts E. Th17 cytokines and arthritis. Semin Immunopathol 2010, 32:43-53.
11. Amarilyo G., Lourenco E.V., Shi F.D., La Cava A. IL-17 promotes murine lupus. J Immunol 2014, 193:540-543.
12. Sawa S., Lochner M., Satoh-Takayama N., Dulauroy S., Berard M., Kleinschek M., et al. RORgammat+ innate lymphoid cells regulate intestinal homeostasis by integrating negative signals from the symbiotic microbiota. Nat Immunol 2011, 12:320-326.
13. Marks B.R., Nowyhed H.N., Choi J.Y., Poholek A.C., Odegard J.M., Flavell R.A., et al. Thymic self-reactivity selects natural interleukin 17-producing T cells that can regulate peripheral inflammation. Nat Immunol 2009, 10:1125-1132.
14. Spits H., Artis D., Colonna M., Diefenbach A., Di Santo J.P., Eberl G., et al. Innate lymphoid cells-a proposal for uniform nomenclature. Nat Rev 2013, 13:145-149.
15. Villanova F., Flutter B., Tosi I., Grys K., Sreeneebus H., Perera G.K., et al. Characterization of innate lymphoid cells in human skin and blood demonstrates increase of NKp44+ ILC3 in psoriasis. J Invest Dermatol 2014, 134:984-991.
16. Gu C., Wu L., Li X. IL-17 family: cytokines, receptors and signaling. Cytokine 2013, 64:477-485.
17. Toy D., Kugler D., Wolfson M., Vanden Bos T., Gurgel J., Derry J., et al. Cutting edge: interleukin 17 signals through a heteromeric receptor complex. J Immunol 2006, 177:36-39.
18. Awane M., Andres P.G., Li D.J., Reinecker H.C. NF-kappa B-inducing kinase is a common mediator of IL-17-, TNF-alpha-, and IL-1 beta-induced chemokine promoter activation in intestinal epithelial cells. J Immunol 1999, 162:5337-5344.
19. Schwandner R., Yamaguchi K., Cao Z. Requirement of tumor necrosis factor receptor-associated factor (TRAF)6 in interleukin 17 signal transduction. J Exp Med 2000, 191:1233-1240.
20. Iwakura Y., Nakae S., Saijo S., Ishigame H. The roles of IL-17A in inflammatory immune responses and host defense against pathogens. Immunol Rev 2008, 226:57-79.
21. Damsker J.M., Hansen A.M., Caspi R.R. Th1 and Th17 cells: adversaries and collaborators. Ann N Y Acad Sci 2010, 1183:211-221.
22. Chu C.Q., Swart D., Alcorn D., Tocker J., Elkon K.B. Interferon-gamma regulates susceptibility to collagen-induced arthritis through suppression of interleukin-17. Arthritis Rheum 2007, 56:1145-1151.
23. Rajaiah R., Puttabyatappa M., Polumuri S.K., Moudgil K.D. Interleukin-27 and interferon-gamma are involved in regulation of autoimmune arthritis. J Biol Chem 2011, 286:2817-2825.
24. Nindl V., Maier R., Ratering D., De Giuli R., Zust R., Thiel V., et al. Cooperation of Th1 and Th17 cells determines transition from autoimmune myocarditis to dilated cardiomyopathy. Eur J Immunol 2012, 42:2311-2321.
25. Sato K., Suematsu A., Okamoto K., Yamaguchi A., Morishita Y., Kadono Y., et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006, 203:2673-2682.
26. Koenders M.I., Lubberts E., Oppers-Walgreen B., van den Bersselaar L., Helsen M.M., Kolls J.K., et al. Induction of cartilage damage by overexpression of T cell interleukin-17A in experimental arthritis in mice deficient in interleukin-1. Arthritis Rheum 2005, 52:975-983.
27. Nanjundaiah S.M., Astry B., Moudgil K.D. Mediators of inflammation-induced bone damage in arthritis and their control by herbal products. Evid Based Complement Alternat Med 2013, 2013:518094.
28. Venkatesha S.H., Yu H., Rajaiah R., Tong L., Moudgil K.D. Celastrus-derived Celastrol suppresses autoimmune arthritis by modulating antigen-induced cellular and humoral effector responses. J Biol Chem 2011, 286:15138-15146.
29. Abu Al Fadl E.M., Fattouh M., Allam A.A. High IL-23 level is a marker of disease activity in rheumatoid arthritis. Egypt J Immunol/Egypt Assoc Immunol 2013, 20:85-92.
30. Guo Y.Y., Wang N.Z., Zhao S., Hou L.X., Xu Y.B., Zhang N. Increased interleukin-23 is associated with increased disease activity in patients with rheumatoid arthritis. Chin Med J 2013, 126:850-854.
31. Metawi S.A., Abbas D., Kamal M.M., Ibrahim M.K. Serum and synovial fluid levels of interleukin-17 in correlation with disease activity in patients with RA. Clin Rheumatol 2011, 30:1201-1207.
32. Bettelli E., Korn T., Kuchroo V.K. Th17: the third member of the effector T cell trilogy. Curr Opin Immunol 2007, 19:652-657.
33. Sutton C.E., Lalor S.J., Sweeney C.M., Brereton C.F., Lavelle E.C., Mills K.H. Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity 2009, 31:331-341.
34. Zhu S., Qian Y. IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential. Clin Sci (Lond) 2012, 122:487-511.
35. Ivanov I.I., McKenzie B.S., Zhou L., Tadokoro C.E., Lepelley A., Lafaille J.J., et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006, 126:1121-1133.
36. Korn T., Bettelli E., Gao W., Awasthi A., Jager A., Strom T.B., et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007, 448:484-487.
37. Acosta-Rodriguez E.V., Napolitani G., Lanzavecchia A., Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007, 8:942-949.
38. Wilson N.J., Boniface K., Chan J.R., McKenzie B.S., Blumenschein W.M., Mattson J.D., et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007, 8:950-957.
39. Yang L., Anderson D.E., Baecher-Allan C., Hastings W.D., Bettelli E., Oukka M., et al. IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature 2008, 454:350-352.
40. Luzza F., Parrello T., Monteleone G., Sebkova L., Romano M., Zarrilli R., et al. Up-regulation of IL-17 is associated with bioactive IL-8 expression in Helicobacter pylori-infected human gastric mucosa. J Immunol 2000, 165:5332-5337.
41. Conti H.R., Shen F., Nayyar N., Stocum E., Sun J.N., Lindemann M.J., et al. Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J Exp Med 2009, 206:299-311.
42. Hernandez-Santos N., Gaffen S.L. Th17 cells in immunity to Candida albicans. Cell Host Microbe 2012, 11:425-435.
43. Puel A., Cypowyj S., Bustamante J., Wright J.F., Liu L., Lim H.K., et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science (New York, NY) 2011, 332:65-68.
44. Puel A., Cypowyj S., Marodi L., Abel L., Picard C., Casanova J.L. Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis. Curr Opin Allergy Clin Immunol 2012, 12:616-622.
45. Conti H.R., Peterson A.C., Brane L., Huppler A.R., Hernandez-Santos N., Whibley N., et al. Oral-resident natural Th17 cells and gammadelta T cells control opportunistic Candida albicans infections. J Exp Med 2014, 211:2075-2084.
46. Milner J.D., Holland S.M. The cup runneth over: lessons from the ever-expanding pool of primary immunodeficiency diseases. Nat Rev 2013, 13:635-648.
47. Archer N.K., Harro J.M., Shirtliff M.E. Clearance of Staphylococcus aureus nasal carriage is T cell dependent and mediated through interleukin-17A expression and neutrophil influx. Infect Immun 2013, 81:2070-2075.
48. Rudner X.L., Happel K.I., Young E.A., Shellito J.E. Interleukin-23 (IL-23)-IL-17 cytokine axis in murine pneumocystis carinii infection. Infect Immun 2007, 75:3055-3061.
49. Golding A., Rosen A., Petri M., Akhter E., Andrade F. Interferon-alpha regulates the dynamic balance between human activated regulatory and effector T cells: implications for antiviral and autoimmune responses. Immunology 2010, 131:107-117.
50. Gratz I.K., Rosenblum M.D., Abbas A.K. The life of regulatory T cells. Ann N Y Acad Sci 2013, 1283:8-12.
51. Sawant D.V., Vignali D.A. Once a Treg, always a Treg?. Immunol Rev 2014, 259:173-191.
52. Chen W., Jin W., Hardegen N., Lei K.J., Li L., Marinos N., et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003, 198:1875-1886.
53. Thornton A.M., Donovan E.E., Piccirillo C.A., Shevach E.M. Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. J Immunol 2004, 172:6519-6523.
54. Wei S., Kryczek I., Edwards R.P., Zou L., Szeliga W., Banerjee M., et al. Interleukin-2 administration alters the CD4+FOXP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma. Cancer Res 2007, 67:7487-7494.
55. Rudensky A.Y. Regulatory T cells and Foxp3. Immunol Rev 2011, 241:260-268.
56. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., Toda M. Pillars article: immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995, 186:3808-3821.
57. Sawla P., Hossain A., Hahn B.H., Singh R.P. Regulatory T cells in systemic lupus erythematosus (SLE); role of peptide tolerance. Autoimmun Rev 2012, 11:611-614.
58. Josefowicz S.Z., Lu L.F., Rudensky A.Y. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol 2012, 30:531-564.
59. Sega E.I., Leveson-Gower D.B., Florek M., Schneidawind D., Luong R.H., Negrin R.S. Role of lymphocyte activation gene-3 (Lag-3) in conventional and regulatory T cell function in allogeneic transplantation. PLoS One 2014, 9:e86551.
60. Tang Q., Bluestone J.A. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol 2008, 9:239-244.
61. You S., Alyanakian M.A., Segovia B., Damotte D., Bluestone J., Bach J.F., et al. Immunoregulatory pathways controlling progression of autoimmunity in NOD mice. Ann N Y Acad Sci 2008, 1150:300-310.
62. Rochman Y., Spolski R., Leonard W.J. New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev 2009, 9:480-490.
63. Vignali D.A. Mechanisms of T(reg) suppression: still a long way to go. Front Immunol 2012, 3:191.
64. Huang C.T., Workman C.J., Flies D., Pan X., Marson A.L., Zhou G., et al. Role of LAG-3 in regulatory T cells. Immunity 2004, 21:503-513.
65. Zhou L., Lopes J.E., Chong M.M., Ivanov I.I., Min R., Victora G.D., et al. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 2008, 453:236-240.
66. Gu Y., Yang J., Ouyang X., Liu W., Li H., Yang J., et al. Interleukin 10 suppresses Th17 cytokines secreted by macrophages and T cells. Eur J Immunol 2008, 38:1807-1813.
67. Heo Y.J., Joo Y.B., Oh H.J., Park M.K., Heo Y.M., Cho M.L., et al. IL-10 suppresses Th17 cells and promotes regulatory T cells in the CD4+ T cell population of rheumatoid arthritis patients. Immunol Lett 2010, 127:150-156.
68. McGovern J.L., Nguyen D.X., Notley C.A., Mauri C., Isenberg D.A., Ehrenstein M.R. Th17 cells are restrained by Treg cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to anti-tumor necrosis factor antibody therapy. Arthritis Rheum 2012, 64:3129-3138.
69. Cooney L.A., Towery K., Endres J., Fox D.A. Sensitivity and resistance to regulation by IL-4 during Th17 maturation. J Immunol 2011, 187:4440-4450.
70. Batten M., Li J., Yi S., Kljavin N.M., Danilenko D.M., Lucas S., et al. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat Immunol 2006, 7:929-936.
71. Chen J., Li J., Gao H., Wang C., Luo J., Lv Z., et al. Comprehensive evaluation of different T-helper cell subsets differentiation and function in rheumatoid arthritis. J Biomed Biotechnol 2012, 2012:535361.
72. Wang W., Shao S., Jiao Z., Guo M., Xu H., Wang S. The Th17/Treg imbalance and cytokine environment in peripheral blood of patients with rheumatoid arthritis. Rheumatol Int 2012, 32:887-893.
73. Lina C., Conghua W., Nan L., Ping Z. Combined treatment of etanercept and MTX reverses Th1/Th2, Th17/Treg imbalance in patients with rheumatoid arthritis. J Clin Immunol 2011, 31:596-605.
74. van Hamburg J.P., Asmawidjaja P.S., Davelaar N., Mus A.M., Colin E.M., Hazes J.M., et al. Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin-17A production. Arthritis Rheum 2011, 63:73-83.
75. Niu Q., Cai B., Huang Z.C., Shi Y.Y., Wang L.L. Disturbed Th17/Treg balance in patients with rheumatoid arthritis. Rheumatol Int 2012, 32:2731-2736.
76. Mijnheer G., Prakken B.J., van Wijk F. The effect of autoimmune arthritis treatment strategies on regulatory T-cell dynamics. Curr Opin Rheumatol 2013, 25:260-267.
77. Jiao Z., Wang W., Jia R., Li J., You H., Chen L., et al. Accumulation of FoxP3-expressing CD4+CD25+ T cells with distinct chemokine receptors in synovial fluid of patients with active rheumatoid arthritis. Scand J Rheumatol 2007, 36:428-433.
78. Mottonen M., Heikkinen J., Mustonen L., Isomaki P., Luukkainen R., Lassila O. CD4+ CD25+ T cells with the phenotypic and functional characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis. Clin Exp Immunol 2005, 140:360-367.
79. van Amelsfort J.M., Jacobs K.M., Bijlsma J.W., Lafeber F.P., Taams L.S. CD4(+)CD25(+) regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid. Arthritis Rheum 2004, 50:2775-2785.
80. Noack M., Miossec P. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun Rev 2014, 13:668-677.
81. Moradi B., Schnatzer P., Hagmann S., Rosshirt N., Gotterbarm T., Kretzer J.P., et al. CD4(+)CD25(+)/highCD127low/(-) regulatory T cells are enriched in rheumatoid arthritis and osteoarthritis joints-analysis of frequency and phenotype in synovial membrane, synovial fluid and peripheral blood. Arthritis Res Ther 2014, 16:R97.
82. Behrens F., Himsel A., Rehart S., Stanczyk J., Beutel B., Zimmermann S.Y., et al. Imbalance in distribution of functional autologous regulatory T cells in rheumatoid arthritis. Ann Rheum Dis 2007, 66:1151-1156.
83. Raghavan S., Cao D., Widhe M., Roth K., Herrath J., Engstrom M., et al. FOXP3 expression in blood, synovial fluid and synovial tissue during inflammatory arthritis and intra-articular corticosteroid treatment. Ann Rheum Dis 2009, 68:1908-1915.
84. Bernard N.J. Rheumatoid arthritis: who knows why regulatory T cells are defective in RA . . . IDO. Nat Rev Rheumatol 2014, 10:381.
85. Kennedy A., Schmidt E.M., Cribbs A.P., Penn H., Amjadi P., Syed K., et al. A novel upstream enhancer of FOXP3, sensitive to methylation-induced silencing, exhibits dysregulated methylation in rheumatoid arthritis Treg cells. Eur J Immunol 2014, 44:2968-2978.
86. Flores-Borja F., Jury E.C., Mauri C., Ehrenstein M.R. Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. Proc Natl Acad Sci USA 2008, 105:19396-19401.
87. Cribbs A.P., Kennedy A., Penn H., Read J.E., Amjadi P., Green P., et al. Treg cell function in rheumatoid arthritis is compromised by ctla-4 promoter methylation resulting in a failure to activate the indoleamine 2,3-dioxygenase pathway. Arthritis Rheumatol (Hoboken, NJ) 2014, 66:2344-2354.
88. Nie H., Zheng Y., Li R., Guo T.B., He D., Fang L., et al. Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-alpha in rheumatoid arthritis. Nat Med 2013, 19:322-328.
89. Duarte J., Agua-Doce A., Oliveira V.G., Fonseca J.E., Graca L. Modulation of IL-17 and Foxp3 expression in the prevention of autoimmune arthritis in mice. PLoS One 2010, 5:e10558.
90. Niu X., He D., Zhang X., Yue T., Li N., Zhang J.Z., et al. IL-21 regulates Th17 cells in rheumatoid arthritis. Hum Immunol 2010, 71:334-341.
91. Fujimoto M., Serada S., Mihara M., Uchiyama Y., Yoshida H., Koike N., et al. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. Arthritis Rheum 2008, 58:3710-3719.
92. Samson M., Audia S., Janikashvili N., Ciudad M., Trad M., Fraszczak J., et al. Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. Arthritis Rheum 2012, 64:2499-2503.
93. Sugita S., Kawazoe Y., Imai A., Yamada Y., Horie S., Mochizuki M. Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behcet's disease. Arthritis Res Ther 2012, 14:R99.
94. Esensten J.H., Wofsy D., Bluestone J.A. Regulatory T cells as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol 2009, 5:560-565.
95. Haque M., Fino K., Lei F., Xiong X., Song J. Utilizing regulatory T cells against rheumatoid arthritis. Front Oncol 2014, 4:209.
96. O'Connor W., Zenewicz L.A., Flavell R.A. The dual nature of T(H)17 cells: shifting the focus to function. Nat Immunol 2010, 11:471-476.
97. Singh B., Schwartz J.A., Sandrock C., Bellemore S.M., Nikoopour E. Modulation of autoimmune diseases by interleukin (IL)-17 producing regulatory T helper (Th17) cells. Indian J Med Res 2013, 138:591-594.
98. Ke Y., Liu K., Huang G.Q., Cui Y., Kaplan H.J., Shao H., et al. Anti-inflammatory role of IL-17 in experimental autoimmune uveitis. J Immunol 2009, 182:3183-3190.
99. Voo K.S., Wang Y.H., Santori F.R., Boggiano C., Wang Y.H., Arima K., et al. Identification of IL-17-producing FOXP3+ regulatory T cells in humans. Proc Natl Acad Sci USA 2009, 106:4793-4798.
100. Mercer F., Khaitan A., Kozhaya L., Aberg J.A., Unutmaz D. Differentiation of IL-17-producing effector and regulatory human T cells from lineage-committed naive precursors. J Immunol 2014, 193:1047-1054.
101. Chao C.C., Chen S.J., Adamopoulos I.E., Davis N., Hong K., Vu A., et al. Anti-IL-17A therapy protects against bone erosion in experimental models of rheumatoid arthritis. Autoimmunity 2011, 44:243-252.
102. Lubberts E., Koenders M.I., Oppers-Walgreen B., van den Bersselaar L., Coenen-de Roo C.J., Joosten L.A., et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 2004, 50:650-659.
103. Genovese M.C., Van den Bosch F., Roberson S.A., Bojin S., Biagini I.M., Ryan P., et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 2010, 62:929-939.
104. Mease P.J., Genovese M.C., Greenwald M.W., Ritchlin C.T., Beaulieu A.D., Deodhar A., et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N. Engl. J. Med. 2014, 370:2295-2306.
105. Patel D.D., Lee D.M., Kolbinger F., Antoni C. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis 2013, 72(Suppl 2):iii116-iii123.
106. Hueber W., Patel D.D., Dryja T., Wright A.M., Koroleva I., Bruin G., et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Translational Med 2010, 2:52-72.
107. Martin D.A., Churchill M., Flores-Suarez L., Cardiel M.H., Wallace D., Martin R., et al. A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis. Arthritis Res Ther 2013, 15:R164.
108. Gottlieb A., Menter A., Mendelsohn A., Shen Y.K., Li S., Guzzo C., et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009, 373:633-640.
109. McInnes I.B., Kavanaugh A., Gottlieb A.B., Puig L., Rahman P., Ritchlin C., et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013, 382:780-789.
110. Ritchlin C., Rahman P., Kavanaugh A., McInnes I.B., Puig L., Li S., et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 2014, 73:990-999.
111. Yang X.P., Ghoreschi K., Steward-Tharp S.M., Rodriguez-Canales J., Zhu J., Grainger J.R., et al. Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat Immunol 2011, 12:247-254.
112. Yang X.O., Panopoulos A.D., Nurieva R., Chang S.H., Wang D., Watowich S.S., et al. STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J Biol Chem 2007, 282:9358-9363.
113. Park J.S., Kwok S.K., Lim M.A., Kim E.K., Ryu J.G., Kim S.M., et al. STA-21, a promising STAT-3 inhibitor that reciprocally regulates Th17 and Treg cells, inhibits osteoclastogenesis in mice and humans and alleviates autoimmune inflammation in an experimental model of rheumatoid arthritis. Arthritis Rheumatol (Hoboken, NJ) 2014, 66:918-929.
114. Yang E.J., Lee J., Lee S.Y., Kim E.K., Moon Y.M., Jung Y.O., et al. EGCG attenuates autoimmune arthritis by inhibition of STAT3 and HIF-1alpha with Th17/Treg control. PLoS One 2014, 9:e86062.
115. Astry B., Venkatesha S., Moudgil K.D. Celastrus-derived Celastrol modulates autoimmune arthritis through cellular immunoregulation immunity & tolerance: 78th cold spring harbor symposium on quantitative biology 2013, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.
116. Jhun J.Y., Moon S.J., Yoon B.Y., Byun J.K., Kim E.K., Yang E.J., et al. Grape seed proanthocyanidin extract-mediated regulation of STAT3 proteins contributes to Treg differentiation and attenuates inflammation in a murine model of obesity-associated arthritis. PLoS One 2013, 8:e78843.
117. Park M.K., Park J.S., Park E.M., Lim M.A., Kim S.M., Lee D.G., et al. Halofuginone ameliorates autoimmune arthritis in mice by regulating the balance between Th17 and Treg cells and inhibiting osteoclastogenesis. Arthritis Rheumatol 2014, 66:1195-1207.
118. Huh J.R., Leung M.W., Huang P., Ryan D.A., Krout M.R., Malapaka R.R., et al. Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing RORgammat activity. Nature 2011, 472:486-490.
119. Solt L.A., Kumar N., Nuhant P., Wang Y., Lauer J.L., Liu J., et al. Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand. Nature 2011, 472:491-494.
120. Ely L.K., Fischer S., Garcia K.C. Structural basis of receptor sharing by interleukin 17 cytokines. Nat Immunol 2009, 10:1245-1251.
121. Ferretti S., Bonneau O., Dubois G.R., Jones C.E., Trifilieff A. IL-17, produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide-induced airway neutrophilia: IL-15 as a possible trigger. J Immunol 2003, 170:2106-2112.
122. Gaffen S.L. Structure and signalling in the IL-17 receptor family. Nat Rev 2009, 9:556-567.
123. Molet S., Hamid Q., Davoine F., Nutku E., Taha R., Page N., et al. IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. J Allergy Clin Immunol 2001, 108:430-438.
124. Moore E.E., Presnell S., Garrigues U., Guilbot A., LeGuern E., Smith D., et al. Expression of IL-17B in neurons and evaluation of its possible role in the chromosome 5q-linked form of Charcot-Marie-Tooth disease. Neuromuscular Disord: NMD 2002, 12:141-150.
125. Moseley T.A., Haudenschild D.R., Rose L., Reddi A.H. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev 2003, 14:155-174.
126. Rickel E.A., Siegel L.A., Yoon B.R., Rottman J.B., Kugler D.G., Swart D.A., et al. Identification of functional roles for both IL-17RB and IL-17RA in mediating IL-25-induced activities. J Immunol 2008, 181:4299-4310.
127. Starnes T., Broxmeyer H.E., Robertson M.J., Hromas R. Cutting edge: IL-17D, a novel member of the IL-17 family, stimulates cytokine production and inhibits hemopoiesis. J Immunol 2002, 169:642-646.
128. Komiyama Y., Nakae S., Matsuki T., Nambu A., Ishigame H., Kakuta S., et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 2006, 177:566-573.
129. Hofstetter H.H., Ibrahim S.M., Koczan D., Kruse N., Weishaupt A., Toyka K.V., et al. Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis. Cell Immunol 2005, 237:123-130.
130. Tzartos J.S., Friese M.A., Craner M.J., Palace J., Newcombe J., Esiri M.M., et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008, 172:146-155.
131. Chen X.Q., Yu Y.C., Deng H.H., Sun J.Z., Dai Z., Wu Y.W., et al. Plasma IL-17A is increased in new-onset SLE patients and associated with disease activity. J Clin Immunol 2010, 30:221-225.
132. Hsu H.C., Yang P., Wang J., Wu Q., Myers R., Chen J., et al. Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol 2008, 9:166-175.
133. Di Cesare A., Di Meglio P., Nestle F.O. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 2009, 129:1339-1350.
134. Lowes M.A., Kikuchi T., Fuentes-Duculan J., Cardinale I., Zaba L.C., Haider A.S., et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008, 128:1207-1211.
135. Zaba L.C., Cardinale I., Gilleaudeau P., Sullivan-Whalen M., Suarez-Farinas M., Fuentes-Duculan J., et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007, 204:3183-3194.
136. Ahern P.P., Izcue A., Maloy K.J., Powrie F. The interleukin-23 axis in intestinal inflammation. Immunol Rev 2008, 226:147-159.
137. Yang X.O., Chang S.H., Park H., Nurieva R., Shah B., Acero L., et al. Regulation of inflammatory responses by IL-17F. J Exp Med 2008, 205:1063-1075.
138. Yen D., Cheung J., Scheerens H., Poulet F., McClanahan T., McKenzie B., et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006, 116:1310-1316.
139. Grieco F.A., Moore F., Vigneron F., Santin I., Villate O., Marselli L., et al. IL-17A increases the expression of proinflammatory chemokines in human pancreatic islets. Diabetologia 2014, 57:502-511.
140. Shao S., He F., Yang Y., Yuan G., Zhang M., Yu X. Th17 cells in type 1 diabetes. Cell Immunol 2012, 280:16-21.
141. Kawaguchi M., Kokubu F., Fujita J., Huang S.K., Hizawa N. Role of interleukin-17F in asthma. Inflamm Allergy Drug Targets 2009, 8:383-389.
142. Ota K., Kawaguchi M., Matsukura S., Kurokawa M., Kokubu F., Fujita J., et al. Potential involvement of IL-17F in asthma. J Immunol Res 2014, 2014:602846.
143. Petersen B.C., Dolgachev V., Rasky A., Lukacs N.W. IL-17E (IL-25) and IL-17RB promote respiratory syncytial virus-induced pulmonary disease. J leukocyte Biol 2014.
144. Kagami S., Rizzo H.L., Kurtz S.E., Miller L.S., Blauvelt A. IL-23 and IL-17A, but not IL-12 and IL-22, are required for optimal skin host defense against Candida albicans. J Immunol 2010, 185:5453-5462.
145. Khader S.A., Bell G.K., Pearl J.E., Fountain J.J., Rangel-Moreno J., Cilley G.E., et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 2007, 8:369-377.
146. Higgins S.C., Jarnicki A.G., Lavelle E.C., Mills K.H. TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells. J Immunol 2006, 177:7980-7989.
147. Aujla S.J., Chan Y.R., Zheng M., Fei M., Askew D.J., Pociask D.A., et al. IL-22 mediates mucosal host defense against gram-negative bacterial pneumonia. Nat Med 2008, 14:275-281.